Replies to post #14811 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I agree, but most institutional investors are sitting on the side until the Libigel results kick in and FDA guidance. I have a good friend who is a regional manager for an investment firm and tweaked me to Biosante for the PDUFA play on Bio-t-gel. Nothing to do with Libigel. I got caught on the December drop and started to investigate. I have brought to his attention the CV data, the patents and the Vaccine award nomination. He was unaware of most of this, as his company has put Biosante on hold until June which is consistent with the conversations he has had with company management in December. Analyst have had similar conversations with Management that is why everyone has placed a hold on the company. I have yet to see an analyst recommend selling Biosante. They are in a hold pattern.

If June provides good news from FDA. The climb will start, the company will no doubt reiterate the good news events that have transpired since December that have been buried by the manipulation. To gain the effect it should of had.